Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028431 · ClinicalTrials.gov registry record · Phase 1
Novel Adjuvants for Peptide-Based Melanoma Vaccines
A Phase 1 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00028431 is a Phase 1 study that has completed, run by University of Southern California. The registered enrollment target is 19 participants.
The verdict
NCT00028431, a Phase 1 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a study to determine the efficacy of a melanoma vaccine chemotherapy cocktail composed of CTLA-4 antibody; tyrosinase, gp100, and MART-1 peptides; and incomplete Freund's adjuvant (IFA) with or without interleukin-12 in patients with resected stage III or IV melanoma.
Interventions
- BIOLOGICAL MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2001-08 |
| Est. Completion | 2005-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028431
The ClinicalTrials.gov registry entry for NCT00028431 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine is the first listed.
NCT00028431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028431 about?
NCT00028431 is a clinical study titled "Novel Adjuvants for Peptide-Based Melanoma Vaccines". This is a study to determine the efficacy of a melanoma vaccine chemotherapy cocktail composed of CTLA-4 antibody; tyrosinase, gp100, and MART-1 peptides; and incomplete Freund's adjuvant (IFA) with or without interleukin-12 in patients with resected stage III or IV melanoma.
What is the current status of trial NCT00028431?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2001-08. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00028431?
The interventions under investigation include: MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00028431?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.